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A series of phosphorylated test peptides was studied by electron capture dissociation Fourier
transform ion cyclotron resonance mass spectrometry (ECD FT-ICR MS). The extensive
ECD-induced fragmentation made identification of phosphorylation sites for these peptides
straightforward. The site(s) of initial phosphorylation of a synthetic peptide with a sequence
identical to that of the phosphorylation site domain (PSD) of the myristoylated alanine-rich C
kinase (MARCKS) protein was then determined. Despite success in analyzing fragmentation of
the smaller test peptides, a unique site on the PSD for the first step of phosphorylation could
not be identified because the phosphorylation reaction produced a heterogeneous mixture of
products. Some molecules were phosphorylated on the serine closest to the N-terminus, and
others on one of the two serines closest to the C-terminus of the peptide. Although no
definitive evidence for phosphorylation on either of the remaining two serines in the PSD was
found, modification there could not be ruled out by the ECD fragmentation data. (J Am Soc
Mass Spectrom 2007, 18, 2137–2145) © 2007 American Society for Mass SpectrometryPost-translational modification of the MARCKSmyristoylated alanine-rich C kinase protein pre-sents an interesting analytical challenge. The
MARCKS protein is a well characterized acidic mem-
brane protein comprised of 309 amino acids, and is
believed to be natively unfolded [1]. It has been impli-
cated in the regulation of brain development [2], cellu-
lar migration [3], cellular adhesion [4], tumor suppres-
sion [5], and neurosecretion [6]. This protein also binds
calmodulin [7], acidic membrane phospholipids [8 –10],
and actin filaments [11]. These interactions are b e l i eved
to be regulated by protein phosphorylation [3, 4, 12,
13]. The MARCKS protein is also a major substrate for
protein kinase C (PKC) [14]. Protein kinase C-related
kinase (PRK1) and -associated kinase also phosphory-
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PKC contains two regions: the N-terminal regulatory
region and the C-terminal catalytic region. This kinase
phosphorylates serine and threonine residues in basic
peptide and protein sequences. Thus, PKC phosphor-
ylates a small segment of the MARCKS protein,
displacing the protein from membranes. The phos-
phorylation of the MARCKS protein then inhibits
cross-linking activity of filamentous (F) actin, calcium-calm-
odulin binding, and binding to the plasma membrane [ 3 , 7 ,
9, 11, 17–19].
The MARCKS protein contains three highly con-
served regions: the phosphorylation site domain (PSD),
the myristoylated amino-terminal domain, and the
MARCKS homology domain. The PSD region, also
known as the effector domain (ED), is the most studied,
and is a basic peptide comprised of 25 amino acid
residues. This region is believed to be central to the
activity of the MARCKS protein. The binding of cal-
modulin and F-actin most likely occurs here [20, 21]. In
addition, an electrostatic interaction between the posi-
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phospholipids also occurs in this region [8 –10]. The
phosphorylation site domain contains five serine candi-
dates for phosphorylation. Phosphorylation of this do-
main may be crucial to the overall function of the
MARCKS protein [3, 4, 22, 23].
Previous studies have simply considered the func-
tion and behavior of the PSD region as an indicator of
the overall function of the MARCKS protein. Although
possibly the PSD peptide behaves differently than the
intact protein, the analytical and biochemical methods
developed for the smaller peptide may also be applica-
ble for study of the intact MARCKS protein [12, 17, 24].
A previous mass spectrometric analysis suggested that
the MARCKS protein may be phosphorylated at sites
other than those of the PSD region. However, LC/
MS/MS spectra showed only b and y-type ions. Phos-
phate loss was also seen, precluding localization of
these modifications [1]. Prior fast-atom bombardment
(FAB) mass spectrometry experiments indicated that
serine residue 2 within the PSD sequence is phosphor-
ylated first, followed by the phosphorylation of serine
residue 1 [25].
Localization of post-translational modifications (PTMs)
such as phosphorylation in protein and peptide mole-
cules is often difficult and time-consuming by use of
standard analytical techniques. Edman degradation and
32P labeling are routinely used to locate phosphoryla-
tion sites [26]. Other techniques include the use of
antibodies, sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), acid hydrolysis, X-ray crys-
tallography, and NMR, all of which can require both
lengthy analysis and large sample volumes [26 –28]. Many
of these problems can be overcome by mass spectrometric
analysis [29].
Electrospray ionization (ESI) coupled to Fourier
transform ion cyclotron resonance mass spectrometry
(FT-ICR MS) has become a popular tool for analysis of
many biomolecules, including peptides and proteins,
due to its low extent of fragmentation, ease of remea-
surement, high mass accuracy, and high mass resolving
power [30 –32]. Traditionally, collision-induced dissoci-
ation (CID) is used to sequence peptides and proteins
[29, 33, 34]. Typically, CID heats the peptide to a higher
Boltzmann temperature [35], often resulting in the loss
of any labile modification during fragmentation. The
presence of the modification is inferred by observing its
loss from the parent ion, but knowledge of the site of
the modification is lost. In contrast, low-energy electron
capture dissociation (ECD) [36 –38] achieves extensive
peptide backbone fragmentation while leaving labile
side-chain modifications intact, thereby enabling more
complete sequencing of the peptides and localization of
the modification. Typically, collisional dissociation gen-
erates b- and y-type ions (i.e., cleavage of the C-N
backbone bond) whereas ECD produces c- and z-type
ions (i.e., cleavage of the C-N backbone bond) as well as
a (i.e., cleavage of the C–C backbone bond) and y-type
ions [33].In this paper, we apply ECD to phosphorylated PSD
with an amino acid sequence identical to that of the
MARCKS protein, in an attempt to identify unique sites
for the first and subsequent steps of phosphorylation.
ECD of a series of singly and doubly phosphorylated
test peptides with amino acid sequences similar to the
PSD was followed by ECD of singly phosphorylated
PSD. Phosphorylation sites in the singly and doubly
modified test peptides were clearly identified, given the
excellent ECD fragmentation efficiency we were able to
obtain. However, results for the singly phosphorylated
PSD segment were ambiguous, with evidence for sev-
eral different sites of phosphorylation.
Experimental
Sample Preparation
Singly and doubly phosphorylated test peptides were
modeled after the sequence of the nonphosphorylated
PSD region (KKKKKRFSFKLSFKLSGFSFKKSKK) of the
MARCKS protein. The MARCKS analogues (Table 1)
each contained 13 amino acid residues, compared with
the 25 amino acids present in the PSD sequence, and
were synthesized to contain only three serine residues,
with a maximum of two serine residues phosphorylated
in any one peptide. The test peptides consisted of three
singly and three doubly phosphorylated peptides, with
a nonphosphorylated peptide used as a control. The
amino acid sequences of all peptides were identical,
differing only in the extent and location of phosphory-
lation. The MARCKS analogues were synthesized at the
University of Florida Protein Core with phosphoryla-
tion at the desired serine residues achieved by incorpo-
rating phosphoserine residues into the peptide se-
quences during the synthesis.
The resulting phosphopeptides were purified by
high-performance liquid chromatography (HPLC) with
a 4.6 mm i.d. C-18 column and a flow rate of 1.0
mL/min. Gradient elution (10%to 80% B) was utilized
(Solvent A: 0.1% TFA/H2O, Solvent B: 0.1% TFA/
ACN), with a total elution period of 32 min.
MALDI-TOF analysis served to confirm the molecu-
lar mass of each purified peptide. The MALDI-TOF
analyses were performed with a Voyager ED-PRO
MALDI-TOF instrument (Applied Biosystems, Foster
Table 1. Predicted monoisotopic masses for the seven
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extraction. An accelerating voltage of 20,000 V was
applied to the ions from each MALDI spot (-cyano-4-
hydroxycinnamic acid matrix), with an extraction pe-
riod of 200 ns. Mass spectra were co-added from 200
laser shots per acquired spectrum.
PSD Phosphorylation
An oligopeptide with an amino acid sequence identical
to that of the phosphorylation site domain (PSD) region
of the MARCKS protein was synthesized at the Univer-
sity of Florida Protein Core. Purification of the synthetic
PSD region again utilized HPLC. MALDI-TOF analysis
was used to confirm the molecular mass of the peptide.
The synthetic PSD segment was diluted to a concentra-
tion of 1 mg/mL in 5 mM MES (2-morpholinoethane
sulfonic acid) buffer (pH 6.0) for use in the phosphor-
ylation reaction. The phosphorylation reaction was
carried out in 50 mM MES (pH 6.0), 1.25 mM EGTA
(ethylene glycol-bis (-aminoethylether)-N,N,N=,N=-
tetraacetic acid) buffer (pH 7.5), 12.5 mM MgCl2, 0.125
mM ATP with 30 ng of rat brain catalytic subunit of
PKC (Calbiochem, San Diego, CA). The reaction was
incubated for 4 h at 30 °C in an agitating water bath.
The reaction was quenched by boiling at 100 °C for 15
min and centrifuging at 14,000 rpm for 15 min in a
tabletop microcentrifuge. The supernatants were col-
lected and desalted before mass spectrometric analysis.
Electron Capture Dissociation Fourier Transform
Mass Spectrometry
Electron capture dissociation experiments were carried
out with a custom-built 9.4 T ESI-Q-FTICR mass spec-
trometer at the National High Magnetic Field Labora-
tory (NHMFL) [39, 40]. Final peptide concentration for
electrospray ionization (Nanomate robot from Advion
Biosciences, Ithaca, NY) was 5 to 10 M in 1:1 acetoni-
trile:water with the addition of 0.1% formic acid. The
ECD experiments were performed with a 10 mm diam-
eter dispenser cathode (Heat Wave Labs, Watsonville,
CA) mounted on the rear of the analyzer cell. The
desired charge state was isolated by an external mass-
selective quadrupole mass filter [41]. The cathode was
operated at a potential of 5 V during the electron
capture events (20 ms irradiation period). A total of 100
single scan acquisitions were co-added for each tandem
mass spectrum.
Data Analysis
Data analysis was carried out with modular ICR data
acquisition system (MIDAS) data analysis software de-
veloped at the NHMFL [42, 43]. Each spectrum was
baseline corrected, Hanning apodized [44] and zero-
filled twice. The thorough high resolution analysis of
spectra by Horn (THRASH) program was used togenerate the experimental peak lists obtained for the
ECD experiments [45]. The monoisotopic masses of
fragment ions were imported into the ProSight PTM
program for generation of the fragmentation summa-
ries [46]. Mass tolerance was 0.1 Da for identifying the
fragment ions. The ProSight program was used to
identify the c/z and b/y ion pairs whereas the a-type ions
were identified from the Protein Prospector database
[47].
Results and Discussion
Figure 1 shows a tandem mass spectrum of a nonphos-
phorylated reference peptide. Nine c-type and 10 z-type
ions were observed, providing complete sequencing. A
series of seven a-type ions was also observed. The result-
ing fragmentation summary, showing all observed frag-
ment ions, can be seen in the inset of Figure 1.
Fragmentation of Singly Phosphorylated
Polypeptides
Figure 2 shows the ECD mass spectrum and resulting
fragmentation summary for the [M  3H]3 charge
state of MARCKS analogue 2 (sequence shown in Table
1). Cleavages occurred at all backbone bonds, resulting
in the formation of 10 c-type and ten z-type ions.
In addition to the most frequent ECD fragment ions,
nine a-type and six y-type ions were also seen. The
fragment ions resulting from cleavage on both the
N-terminal and C-terminal sides of the modified resi-
due correctly indicate the presence of the modification
on Ser 3. There are no fragments consistent with phos-
phorylation of either Ser 7 or Ser 10. Similar scenarios
were seen for MARCKS analogues 3 and 4. In each case,
the site of phosphorylation was correctly assigned to
Ser 7 or Ser 10, respectively.
Figure 1. ECD FT-ICR mass spectrum of MARCKS analogue 1.
All N-C backbone bonds were cleaved. All labeled fragment ions
are singly charged. As shown in the inset, a single bracket denotes
that only c or z ions were seen for that bond cleavage. The double
bracket denotes the presence of a- or y-ions in addition to c- or
z-ions. The same fragmentation designation is used in Figures 2, 3,
and Schemes 1–4.
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Polypeptides
Figure 3 shows the ECD mass spectrum for MARCKS
analogue 5 (sequence shown in Table 1). S e r 3 a n d S e r
7 were phosphorylated in this peptide, whereas Ser
10 was not modified. Cleavage occurred at all back-
bone bonds, allowing for complete sequencing of this
phosphopeptide.
A total of 34 fragment ions was formed, permitting
localization of the sites of phosphorylation. The frag-
ment ions on the N-terminal (z11) and C-terminal (c3)
sides of Ser 3 indicate the presence of a phosphate
group. Fragment ions z7 and c7 indicate the presence of
a modification on Ser 7. The fragment ions surrounding
Ser 10 show an unmodified residue at that position.
Similar scenarios were seen for MARCKS analogues 6
and 7 (sequences shown in Table 1). In each case, the
sites of phosphorylation could be localized to the cor-
rect serine residues (Scheme 1).
The relative abundances of the resulting fragment
ions were explored in an attempt to determine if there
Figure 2. ECD FT-ICR mass spectrum of MARCKS analogue 2.
All N-C backbone bonds were cleaved, allowing localization of
the site of phosphorylation to Ser 3. All fragment ions are singly
charged. The phosphoserine residue (Ser 3) is denoted by pS.
Figure 3. ECD FT-ICR mass spectrum of MARCKS analogue 5.
The sites of phosphorylation were correctly assigned to Ser 3 and
Ser 7. All fragment ions are singly charged.was a distinct pattern to the retention or loss of the
phosphate group. The relative abundances for the a-
type ions of the doubly phosphorylated MARCKS ana-
logue peptides (Figure 4) provide information regard-
ing the abundances of the modified residues.
The only a-type ions were from the unmodified
residues. There were no a-ions representing fragmenta-
tion on the C-terminal side of the phosphorylated
residues in each of the doubly phosphorylated pep-
tides. As an example, for MARCKS analogue 7, frag-
ment ions a3 and a7 would represent fragmentation
Scheme 1. Fragmentation summaries obtained for the electron
capture dissociation of the MARCKS analogues. In each case, the
sites of phosphorylation could be localized to the correct serine
residues.
Figure 4. a-Ion relative abundance histogram for the doubly
phosphorylated MARCKS analogues. The a-ions provide com-
plementary structural information for the phosphorylation site
determination.
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not present. However, there is a fragment ion in the
experimental peak list that corresponds to the loss of
the modification from the serine residue (a7-phosphate).
It could not be determined if the same is true for
fragment ion a3, because that m/z value falls below the
scanned mass range.
It should be noted that a similar trend was not seen
for the singly phosphorylated peptides. Their a-type
ions corresponded to cleavage on the C-terminal side of
the modified residues. There was no evidence that the
phosphate groups were lost during the dissociation
process, as for the doubly phosphorylated peptides. The
trend for the doubly phosphorylated peptides may or
may not hold true for other modified peptides. Because
the loss of the modification is usually not seen in
electron capture dissociation, future work should focus
on determining the relative abundances of the a-type
ions for other multiply-modified peptides.
Differentiation of Polypeptides with Identical Mass
and Number of Modifications
The results reported above clearly indicate (as have
earlier studies) [33, 48 –51] that ECD can be used to
confirm known structures of phosphorylated peptides.
However, analyzing peptides with unknown sites of
phosphorylation can nevertheless occasionally be prob-
lematic. As seen in Table 1, MARCKS analogues 2, 3,
and 4 each have the same molecular mass and number
of modifications as do MARCKS analogues 5, 6, and 7.
We simulated the analysis of peptides with unknown
sites of phosphorylation, based on our test peptides, by
comparing the predicted ECD fragments for two of the
mono- (or di-)phosphorylated peptides with the actual
experimental ECD fragments obtained from the third
mono- (or di-)phosphorylated peptide. All possible
comparisons were made.
The experimental peak lists obtained for each of the
singly phosphorylated peptides were compared with
those predicted for each of the other two singly modi-
fied peptides in turn to determine how many of the
experimental fragment ions were identical to those
predicted for each peptide. Based upon the theoretically
obtained peak lists, several fragment ions for each of the
singly phosphorylated peptides were predicted to be
identical, whereas the remaining ions differ (due to
different sites of phosphorylation) for each of the re-
spective peptides. The fragment ions unique to each
peptide should have been found only in the experimen-
tally generated peak list for the “correct” peptide. As an
example, fragment ions c7 and z11 should be identical
for peptides 2 and 3 whereas fragment ion c3 should be
different. The fragment ions that differ from peptide to
peptide should provide a means of unambiguously
differentiating between each of the similar peptides. An
analogous scenario should hold true for the doubly
phosphorylated peptides.The experimental peak list for MARCKS analogue 3
was compared with those predicted for peptides 2 and
4 (Scheme 2) to determine if the site of phosphorylation
could be unambiguously determined. For peptide 2, 21
predicted fragment ions matched those obtained for
peptide 3. Each of the 21 fragment ions could be
attributed to peptide 3.
The presence of fragment ion z11 indicates that any of
the three serine residues may be phosphorylated
whereas fragment ion c7 indicates that the lone modifi-
cation may be located on either Ser 3 or Ser 7. The exact
location cannot be determined based upon the theoret-
ically generated list of fragment ions. A similar scenario
was seen for peptide 4 (with the peak list for peptide 3).
Twenty-two fragment ions matched, with no discrep-
ancies. Fragment ion z7 indicates phosphorylation on
Ser 7 or Ser 10 whereas fragment ion c10 indicates that
any of the three serine residues may be modified.
Further localization is not possible (Scheme 2).
An analogous procedure was carried out for each of
the doubly phosphorylated peptides. For example, the
experimentally obtained peak list for MARCKS ana-
logue 6 was compared with those theoretically pre-
dicted for MARCKS analogues 5 and 7. Scheme 3 shows
the predicted fragments for each of the doubly phos-
phorylated peptides that match the experimentally ob-
tained peak list for peptide 6. For the predicted peaks
from peptide 5 (based on the experimental peak list for
peptide 6), 22 fragment ions matched. All fragment
ions produced by electron capture dissociation were
consistent with fragmentation from MARCKS ana-
logue 6, but there was no agreement between exper-
imental peaks from analogue 6 and predicted peaks
from analogue 5 that would suggest phosphorylation
on the second serine in the sequence (appropriate to
analogue 5) rather than the third serine (appropriate
Scheme 2. ECD correlation analysis for MARCKS analogues
2–4. The peak list obtained from the ECD of MARCKS analogue 3
was compared with that predicted for analogues 2 and 4. The
fragment ions shown are those that match the experimental peak
list for analogue 3.to analogue 6, and from which the experimental peak
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tion could not be assigned if the “wrong” predicted
peak list were compared with the experiment data. If
the predicted fragment ions for peptide 7 were com-
pared with the experimental peak list for peptide 6,
19 fragment ions matched, but again no fragments
were seen that would lead to mis-assignment of the
sites of phosphorylation.
Schemes 2 and 3 illustrate the need for fragment ions
on both sides of the modified amino acid residues for
complete localization of the modification (or modifica-
tions). For each scenario, the “missing” fragment ions
would be present in the predicted peak lists of the
“wrong” peptides only if the sites of phosphorylation
were different from those in the peptide for which
experimental data were obtained. Although a few dis-
crepancies did arise (data not shown), the sites of
phosphorylation for the actual sequences, based on the
experimentally obtained peak lists, were correctly iden-
tified only by use of the “correct” peak lists.
Given the success of identifying the sites of phos-
phorylation in singly and doubly modified MARCKS
PSD analogues, and the ability to tell that singly and
doubly phosphorylated sites of “unknowns” were not
at possible locations of a peptide with known phos-
phorylation sites, we next proceeded to analysis of the
singly phosphorylated peptide with a sequence identi-
cal to the PSD region of the MARCKS protein.
Application of Fragmentation Guidelines
to the PSD Polypeptide
The synthetic PSD segment was phosphorylated in
Scheme 3. ECD correlation analysis for MARCKS analogues 5–7.
The peak list obtained for the ECD of analogue 6 was compared
with those predicted for analogues 5 and 7. The fragment ions
shown are those that match the experimental peak list for
analogue 6.vitro and subjected to electron capture dissociationmass spectrometry. The extent of phosphorylation was
not known before the mass spectrometric analysis. The
precursor mass spectrum (data not shown) showed both a
singly phosphorylated and a doubly phosphorylated PSD
segment. The abundances of doubly phosphorylated ions
were insufficient for reliable ECD fragmentation. The 4
charge state of the singly phosphorylated PSD segment
was isolated by SWIFT excitation [52, 53] and subjected
to ECD, Figure 5.
Because the PSD region contains five serines that
may be phosphorylated, all resulting in ions with
identical mass, five different peptide sequences are
possible for this polypeptide. In an approach similar to
that described above for the test peptides, we compared
the experimentally obtained fragment peak list in turn
with that predicted for PSD phosphorylated at each of
the five serine residues.
The experimental fragment ions matching those pre-
dicted for serine 1 phosphorylation (and a similar
representation for the PSD phosphorylated at each of
the other four serine residues) are shown in Scheme 4.
The presence of c8 (m/z 1128.7008), c9, c10, andc11 frag-
ment ions indicates that some portion of the sample
mixture is phosphorylated at Ser 8. There are fragment
ions that correspond to cleavage on either the N-
terminal or C-terminal sides, or both, of the remaining
(unmodified) serine residues.
Fragment ion c12 might suggest modification at Ser
12. However, that ion mass is identical to that of the c12
fragment that would be obtained from PSD phosphor-
ylated at Ser 8 (as are the c13 through c24 fragment ions),
so the presence of those ions does not prove that an
additional fraction of the sample is phosphorylated at
Ser 12. However, some of the peptide molecules are
phosphorylated at a serine residue other than Ser 8, as
evidenced by the presence of c8 (m/z 1048.7478), c9, c10,
Figure 5. ECDmass spectrum for the singly phosphorylated PSD
segment. The precursor ion was isolated by SWIFT excitation
before electron capture dissociation.
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phorylation at Ser 8. In addition, it should be noted that
the presence of fragment ions z15, z16, and z17 indicates
that one of Ser 12, Ser 16, Ser 19, or Ser 23 is modified.
The mixture is apparently heterogeneous, making as-
signment of the fragment ions to one particular PSD
sequence impossible. No fragment ions corresponding
to two cleavages, one on either side of a phosphorylated
“internal” serine residue, were seen. Thus it is not
possible to assign single phosphorylation unambigu-
ously to Ser 12, Ser 16, or Ser 19.
Because positive identification of serine phosphory-
lation at Ser 8 was possible from comparison of exper-
imental fragment ions with those predicted for a single
cleavage for that species (c8, c9, c10, and c11 ions, as
discussed above), the species predicted for ECD of ions
phosphorylated at the other “external” serine residue,
Ser 23, are next compared with those found experimen-
tally (Scheme 4). The absence of experimental fragment
ions with masses corresponding to those predicted for
z3, z4, z5, or z6 ions from PSD modified at Ser 23 strongly
suggests that none of the singly phosphorylated PSD
peptide molecules are modified at Ser 23. Possibly a
very small fraction of the sample is phosphorylated at
Ser 23, but the ECD fragment ions produced from it do
not have sufficient signal-to-noise to be detected. That
ions with masses identical to those predicted for c18
(and a18) fragments are seen in the experimental spec-
trum indicates that some portion of the sample is
phosphorylated at either Ser 19 or Ser 23. Similar
observation of ions with masses identical to those
predicted for c12 and c13 indicates that some fraction of
the sample is phosphorylated at either Ser 16, Ser 19, or
Ser 23.
The fragmentation summaries for Ser 16 and Ser 19
phosphorylation (also shown in Scheme 4) provide no
additional information; each is consistent with possible
Scheme 4. Fragmentation summaries for each unique sequence
combination for the singly phosphorylated PSD segment. Each
fragmentation summary was produced by comparing the experi-
mentally obtained peak list from the electron capture dissociation
experiment with the theoretically predicted peak list for each
sequence combination.phosphorylation at any of the five sites. However, theagreement of the predicted z7 fragment ion peak for
phosphorylation at Ser 19 with one observed experi-
mentally reinforces the conclusion drawn in the last
paragraph that some fraction of the sample is phosphor-
ylated on either Ser 19 or Ser 23.
It is apparent from the results presented above that
in vitro phosphorylation of the PSD peptide results in
single phosphorylation of at least two different serine
residues. At least some of the phosphorylation takes
place at Ser 8, and a second portion of the sample is
phosphorylated at either Ser 19 or Ser 23, with Ser 19
most likely since no direct evidence was seen for
phosphorylation at Ser 23. Although no definitive evi-
dence was found for phosphorylation of Ser 12 or Ser
16, those modifications cannot be ruled out based on the
ECD peaks seen.
These results show that while ECD fragmentation
patterns may be quite unambiguous for small peptides
with one or two known sites of phosphorylation, defin-
itive assignment of phosphorylation sites for larger
peptides with numerous possible sites for modification
is far from straightforward. Future experiments will
attempt to obtain doubly phosphorylated PSD peptides
in sufficient quantity to provide additional information
about the second site of phosphorylation and will
explore more vigorous ECD conditions that might pro-
duce fragmentation of two bonds on either side of
phosphorylated “internal” serine residues. It is also
possible that detailed examination of the abundances of
ECD fragment ions might provide additional informa-
tion as to the probability of phosphorylation at each
possible site, similar to results recently reported for
histone acetylation [54].
Our results are not in agreement with the previous
FAB MS study [25] that predicted that Ser 12 was the
first to be phosphorylated in the PSD peptide. Although
we cannot rule out the possibility that some fraction of
the sample is initially phosphorylated on Ser 12, it is
also clear that other fractions are initially phosphory-
lated on Ser 8 and on Ser 19 or Ser 23 (probably Ser 19).
The previous study was based on a PSD segment that
contained 21 amino acid residues, rather than the 25
amino acid peptide in the current set of experiments. In
addition, the peptide studied previously contained four
serine residues (consistent with human PSD), not five
like ours (consistent with murine PSD), that could
potentially be phosphorylated. Those differences in the
PSD segments could affect the phosphorylation site(s)
found by mass spectrometric analysis. However, it is
unlikely that the discrepancies can be explained by
major structural differences between the peptides be-
cause they are both likely to exhibit highly extended
structures in solution.
Conclusions
Electron capture dissociation Fourier transform ion
cyclotron resonance mass spectrometry was success-
fully utilized to determine the sites of phosphorylation
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peptides (MARCKS analogues), based on extremely
efficient fragmentation. In all cases both the singly and
doubly modified polypeptide fragment ions on both the
N-terminal and C-terminal sides of the modified resi-
due (or residues) could be used to identify the site(s) of
phosphorylation unambiguously.
ECD experiments based on the same approach were
applied to a singly phosphorylated peptide with a
sequence identical to that of the phosphorylation site
domain (PSD) of the MARCKS protein, containing five
potentially modifiable serine residues. The efficiency of
fragmentation was reduced compared with the smaller
test peptides, and we were unable to obtain a peak of
sufficient magnitude for the doubly phosphorylated
PSD peptide to enable ECD experiments. We found for
the singly phosphorylated peptide that phosphoryla-
tion was not localized exclusively on any one site. The
results indicate that some of the peptide molecules are
modified at Ser 8 and others at either Ser 19 or Ser 23,
most likely Ser 19. Phosphorylation at Ser 12 or Ser 16
cannot be ruled out, although no direct evidence for it
was seen. The addition of the phosphate group is
apparently not directed to one thermodynamically or
kinetically favored serine during the in vitro phosphor-
ylation reaction. Although the heterogeneity of the
sample mixture complicated interpretation of the ECD
data, it was still possible to gain some knowledge as to
the exact site (or sites) for the initial step of phosphor-
ylation of this peptide.
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